News
All
- Agios Stories
- In The News
After selling off Tibsovo and entire cancer pipeline, Agios nets first approval for new ‘anchor product’
Read More
Agios’ first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder
Read More
Agios wins FDA approval for pill to treat rare blood disease
Read More
Behind the Scenes with Agios Chief Medical Officer, Dr. Sarah Gheuens, on Just Listen: Voices of PK Deficiency Podcast
Read More
Dr. Sarah Gheuens, Agios Chief Medical Officer, on Cheat Codes: A Sickle Cell Podcast
Read More
When it comes to employee mental health, these companies put in the work
Read More
Our Approach to Partnering with Patients on CheatCodes: A Sickle Cell Podcast
Read More
Jackie Fouse: What The Sale Of Agios’ Oncology Pipeline Taught Me
Read More
100 Most Sustainable Companies
Read More
More Positive Data Sets Up Agios’ Mitapivat for Regulatory Filings This Year
Read More
Agios to Sell Cancer Portfolio to Servier for $1.8 Billion
Read More
Changing identity, Agios to sell cancer drug business to Servier
Read More
Cambridge biotech Agios will sell oncology business to Boston’s Servier for up to $2 billion
Read More
Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases
Read More
Agios’ anemia drug hits goal in phase 3, teeing up 2021 filing
Read More
Agios CEO Jackie Fouse on FDA Orphan Drug Designated Mitapivat
Read More
Why Go To The Office? Few Want To — Some Need To
Read More
Cancer drugmaker Agios offers promising data from two studies testing blood disorder drug
Read More
Agios drug demonstrates strong response in patients with inherited blood disorder
Read More
Agios CEO Jackie Fouse weighs in on the healthcare space
Read More
Jackie Fouse, Admired By Investors, To Become CEO Of Biotech Agios
Read More